Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...

AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...

The new first-line MCL indication gives Calquence a slice of the market of its own and could spur further growth of the drug, ...

Pirtobrutinib (brand name Jaypirca) could reduce progression or death risk by 46% in patients with chronic lymphocytic ...

Immediate gastrectomy was performed due to perforation. Histopathological examination diagnosed a triple-expressor gastric Diffuse Large B-Cell Lymphoma (DLBCL) [Bcl-2 focal (60%), Bcl-6 focal (40%), ...

However, newer treatment regimens may increase survival. Incidence of EATL in the U.S. appears to be increasing, according to a 2012 study in the journal Cancer. The authors said this may reflect ...

Survival games simulate ancestral activities for modern players without real-life consequences. Various survival games offer challenging gameplay mechanics that test players' skill and ...